Clinical trial
A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma
NCT00683449 is registered in ClinicalTrials.gov with MediciNova as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma
- Lead sponsor
- MediciNova
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 30, 2008
- Completion date
- March 31, 2009
- Enrollment
- 29 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.